Progress toward inhibitors of metallo-β-lactamases

Future Medicinal Chemistry

Volumn 9, Issue 7, 2017, Pages 673-691

  McGeary, Ross P ^a   Tan, Daniel Tc ^a   Schenk, Gerhard ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

antibiotics; bacterial resistance; metalloenzymes

Indexed keywords

6 (MERCAPTOMETHYL)PENICILLINATE; ALCOHOL DERIVATIVE; AMPICILLIN; BENZENE DERIVATIVE; BETA LACTAMASE INHIBITOR; BIPHENYLTETRAZOLE; BORONIC ACID DERIVATIVE; CAPTOPRIL; DICARBOXYLIC ACID; IMIPENEM; IMIPENEMASE; MERCAPTOPHOSPHONATE; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE INHIBITOR; PENICILLIN DERIVATIVE; PYRROLE DERIVATIVE; RHODANINE; THIOGLYCOLIC ACID; THIOL; TRIFLUOROMETHYL ALCOHOL; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

DRUG SCREENING; ELECTROSPRAY; ENZYME ACTIVITY; FLUORINE NUCLEAR MAGNETIC RESONANCE; GEL FILTRATION; IC50; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIUM; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85019738771     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2017-0007     Document Type: Review

References (83)

1. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105(2), 395-424 (2005).
2. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-lactamases: the quiet before the storm Clin. Microbiol. Rev. 18(2), 306-325 (2005).
3. Crowder MW, Spencer J, Vila AJ. Metallo-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39(10), 721-728 (2006).
4. Bush K, Jacoby GA. Updated functional classification of-lactamases. Antimicrob. Agents Chemother. 54(3), 969-976 (2010).
5. Ball P. The clinical development and launch of amoxicillin/ clavulanate for the treatment of a range of communityacquired infections. Int. J. Antimicrob. Agents 30(Suppl. 2), S113-S117 (2007).
6. Cahill ST, Tarhonskaya H, Rydzik AM et al. Use of ferrous iron by metallo-lactamases. J. Inorg. Biochem. 163 185-193 (2016).
7. Selleck C, Larrabee JA, Harmer J et al. AIM-1: an antibioticdegrading metallohydrolase that displays mechanistic flexibility. Chem. Eur. J. 22(49), 17704-17714 (2016).
8. Bebrone C. Metallo-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74(12), 1686-1701 (2007).
9. Hou C-FD, Phelan EK, Miraula M, Ollis DL, Schenk G, Mitic N. Unusual metallo-lactamases may constitute a new subgroup in this family of enzymes. Am. J. Mol. Biol. 4(1), 11-15 (2014).
10. Vella P, Miraula M, Phelan E et al. Identification and characterization of an unusual metallo-lactamase from Serratia proteamaculans. J. Biol. Inorg. Chem. 18(7), 855-863 (2013).
11. Toney JH, Hammond GG, Fitzgerald PMD et al. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-lactamase. J. Biol. Chem. 276(34), 31913-31918 (2001).
12. Garau G, Bebrone C, Anne C, Galleni M, Frère JM, Dideberg O. A metallo-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J. Mol. Biol. 345(4), 785-795 (2005).
13. Spencer J, Read J, Sessions RB, Howell S, Blackburn GM, Gamblin SJ. Antibiotic recognition by binuclear metallo-lactamases revealed by x-ray crystallography. J. Am. Chem. Soc. 127(41), 14439-14444 (2005).
14. Mcgeary RP, Schenk G, Guddat LW. The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-lactamases and arginases. Eur. J. Med. Chem. 76 132-144 (2014).
15. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
16. Phelan EK, Miraula M, Selleck C, Ollis DL, Schenk G, Mitic N. Metallo-lactamases: a major threat to human health. Am. J. Mol. Biol. 4(3), 89-104 (2014).
17. Hou C-FD, Liu J-W, Collyer C et al. Insights into an evolutionary strategy leading to antibiotic resistance. Sci. Rep. 7, 40357 (2017).
18. Pegg KM, Liu EM, George AC et al. Understanding the determinants of substrate specificity in IMP family metallo-lactamases: the importance of residue 262. Protein Sci. 23(10), 1451-1460 (2014).
19. Gonzalez LJ, Moreno DM, Bonomo RA, Vila AJ. Hostspecific enzyme-substrate interactions in SPM-1 metallo-lactamase are modulated by second sphere residues. PLoS Pathog. 10(1), e1003817 (2014).
20. Livermore DM. Fourteen years in resistance. Int. J. Antimicrob. Agents 39(4), 283-294 (2012).
21. Guerra B, Fischer J, Helmuth R. An emerging public health problem: acquired carbapenemase-producing microorganisms are present in food-producing animals, their environment, companion animals and wild birds. Vet. Microbiol. 171(3-4), 290-297 (2014).
22. Zhang H, Hao Q. Crystal structure of NDM-1 reveals a common-lactam hydrolysis mechanism. FASEB J. 25(8), 2574-2582 (2011).
23. Laraki N, Franceschini N, Rossolini GM et al. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43(4), 902-906 (1999).
24. Siemann S, Brewer D, Clarke AJ, Dmitrienko GI, Lajoie G, Viswanatha T. IMP-1 metallo-lactamase: effect of chelators and assessment of metal requirement by electrospray mass spectrometry. Biochim. Biophys. Acta 1571(3), 190-200 (2002).
25. Chen P, Horton LB, Mikulski RL et al. 2-substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-lactamases. Bioorg. Med. Chem. Lett. 22(19), 6229-6232 (2012).
26. Roll DM, Yang Y, Wildey MJ, Bush K, Lee MD. Inhibition of metallo-lactamases by pyridine monothiocarboxylic acid analogs. J. Antibiot. 63(5), 255-257 (2010).
27. Horsfall LE, Garau G, Liénard BMR et al. Competitive inhibitors of the CphA metallo-lactamase from Aeromonas hydrophila. Antimicrob. Agents Chemother. 51(6), 2136-2142 (2007).
28. Yang Y, Bush K. Biochemical characterization of the carbapenem-hydrolyzing-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-lactamases. FEMS Microbiol. Lett. 137(2-3), 193-200 (1996).
29. Somboro AM, Tiwari D, Bester LA et al. NOTA: a potent metallo-lactamase inhibitor. J. Antimicrob. Chemother. 70(5), 1594-1596 (2015).
30. Liao D, Yang S, Wang J et al. Total synthesis and structural reassignment of Aspergillomarasmine A. Angew. Chem. Int. Ed. Engl. 55(13), 4291-4295 (2016).
31. King AM, Reid-Yu SA, Wang W et al. Aspergillomarasmine A overcomes metallo-lactamase antibiotic resistance. Nature 510(7506), 503-506 (2014).
32. Walter MW, Felici A, Galleni M et al. Trifluoromethyl alcohol and ketone inhibitors of metallo-lactamases. Bioorg. Med. Chem. Lett. 6(20), 2455-2458 (1996).
33. Toney JH, Fitzgerald PMD, Grover-Sharma N et al. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-lactamase. Chem. Biol. 5(4), 185-196 (1998).
34. Albu SA, Koteva K, King AM, Al-Karmi S, Wright GD, Capretta A. Total synthesis of Aspergillomarasmine A and related compounds: a sulfamidate approach enables exploration of structure-activity relationships. Angew. Chem. Int. Ed. 55(42), 13259-13262 (2016).
35. Christianson DW, Lipscomb WN. Complex between carboxypeptidase A and a possible transition-state analog: mechanistic inferences from high-resolution x-ray structures of enzyme-inhibitor complexes. J. Am. Chem. Soc. 108(16), 4998-5003 (1986).
36. Hiraiwa Y, Morinaka A, Fukushima T, Kudo T. Metallo-lactamase inhibitory activity of phthalic acid derivatives. Bioorg. Med. Chem. Lett. 19(17), 5162-5165 (2009).
37. Livermore DM, Mushtaq S, Morinaka A, Ida T, Maebashi K, Hope R. Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J. Antimicrob. Chemother. 68(1), 153-158 (2013).
38. Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. In vitro potentiation of carbapenems with ME1071, a novel metallo-lactamase inhibitor, against metallo-lactamaseproducing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 54(9), 3625-3629 (2010).
39. Yamada K, Yanagihara K, Kaku N et al. In vivo efficacy of biapenem with ME1071, a novel metallo-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 42(3), 238-243 (2013).
40. Hiraiwa Y, Saito J, Watanabe T et al. X-ray crystallographic analysis of IMP-1 metallo-lactamase complexed with a 3-aminophthalic acid derivative, structure-based drug design, and synthesis of 3,6-disubstituted phthalic acid derivative inhibitors. Bioorg. Med. Chem. Lett. 24(20), 4891-4894 (2014).
41. Olsen L, Jost S, Adolph H-W, Pettersson I, Hemmingsen L, Jorgensen FS. New leads of metallo-lactamase inhibitors from structure-based pharmacophore design. Bioorg. Med. Chem. 14(8), 2627-2635 (2006).
42. Hiraiwa Y, Morinaka A, Fukushima T, Kudo T. Metallo-lactamase inhibitory activity of 3-alkyloxy and 3-amino phthalic acid derivatives and their combination effect with carbapenem. Biorg. Med. Chem. 21(18), 5841-5850 (2013).
43. Moloughney JG, D. Thomas J, Toney JH. Novel IMP-1 metallo-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol. Lett. 243(1), 65-71 (2005).
44. Payne DJ, Bateson JH, Gasson BC et al. Inhibition of metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives. Antimicrob. Agents Chemother. 41(1), 135-140 (1997).
45. Greenlee ML, Laub JB, Balkovec JM et al. Synthesis and SAR of thioester and thiol inhibitors of IMP-1 Metallo-Lactamase. Bioorg. Med. Chem. Lett. 9(17), 2549-2554 (1999).
46. Hammond GG, Huber JL, Greenlee ML et al. Inhibition of IMP-1 metallo-beta-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. FEMS Microbiol. Lett. 179(2), 289-296 (1999).
47. Liu X-L, Shi Y, Kang JS, Oelschlaeger P, Yang K-W. Amino acid thioester derivatives: a highly promising scaffold for the development of metallo-lactamase L1 inhibitors. ACS Med. Chem. Lett. 6(6), 660-664 (2015).
48. Goto M, Takahashi T, Yamashita F et al. Inhibition of the metallo-lactamase produced from Serratia marcescens by thiol compounds. Biol. Pharm. Bull. 20(11), 1136-1140 (1997).
49. Mollard C, Moali C, Papamicael C et al. Thiomandelic acid, a broad spectrum inhibitor of zinc-lactamases. J. Biol. Chem. 276(48), 45015-45023 (2001).
50. Liu X-L, Yang K-W, Zhang Y-J et al. Optimization of amino acid thioesters as inhibitors of metallo-lactamase L1. Bioorg. Med. Chem. Lett. 26(19), 4698-4701 (2016).
51. Bounaga S, Laws AP, Galleni M, Page MI. The mechanism of catalysis and the inhibition of the Bacillus cereus zinc-dependent-lactamase. Biochem. J. 331(3), 703-711 (1998).
52. Li N, Xu Y, Xia Q et al. Simplified captopril analogues as NDM-1 inhibitors. Bioorg. Med. Chem. Lett. 24(1), 386-389 (2014).
53. Lienard BMR, Garau G, Horsfall L et al. Structural basis for the broad-spectrum inhibition of metallo-lactamases by thiols. Org. Biomol. Chem. 6(13), 2282-2294 (2008).
54. Arjomandi OK, Hussein WM, Vella P et al. Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-lactamase IMP-1. Eur. J. Med. Chem. 114 318-327 (2016).
55. Ma J, Cao Q, Mcleod SM et al. Target-based whole-cell screening by 1H NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 54(16), 4764-4767 (2015).
56. Vella P, Hussein WM, Leung EWW et al. The identification of new metallo-lactamase inhibitor leads from fragmentbased screening. Bioorg. Med. Chem. Lett. 21(11), 3282-3285 (2011).
57. Faridoon, Hussein WM, Vella P et al. 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-lactamase inhibitors. Bioorg. Med. Chem. Lett. 22(1), 380-386 (2012).
58. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nat. Med. 5(10), 1110-1112 (1999).
59. Heinz U, Bauer R, Wommer S et al. Coordination geometries of metal ions in d-or l-Captopril-inhibited metallo-lactamases. J. Biol. Chem. 278(23), 20659-20666 (2003).
60. Thomas PW, Spicer T, Cammarata M, Brodbelt JS, Hodder P, Fast W. An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening. Biorg. Med. Chem. 21(11), 3138-3146 (2013).
61. Guo Y, Wang J, Niu G et al. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein Cell 2(5), 384-394 (2011).
62. Garcia-Saez I, Hopkins J, Papamicael C et al. The 1.5-° structure of Chryseobacterium meningosepticum zinc-lactamase in complex with the inhibitor, d-captopril. J. Biol. Chem. 278(26), 23868-23873 (2003).
63. Garcia-Saez I, Mercuri PS, Papamicael C et al. Threedimensional structure of FEZ-1, a monomeric subclass B3 metallo-lactamase from Fluoribacter gormanii, in native form and in complex with d-captopril. J. Mol. Biol. 325(4), 651-660 (2003).
64. Nauton L, Kahn R, Garau G, Hernandez JF, Dideberg O. Structural insights into the design of inhibitors for the L1 metallo-lactamase from Stenotrophomonas maltophilia. J. Mol. Biol. 375(1) 257-269 (2008).
65. Brem J, Van Berkel SS, Zollman D et al. Structural basis of metallo-beta-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother. 60(1) 142-150 (2015).
66. Yusof Y, Tan DTC, Arjomandi OK, Schenk G, Mcgeary RP. Captopril analogues as metallo-lactamase inhibitors. Bioorg. Med. Chem. Lett. 26(6), 1589-1593 (2016).
67. King DT, Worrall LJ, Gruninger R, Strynadka NCJ. New Delhi metallo-lactamase: structural insights into-lactam recognition and inhibition. J. Am. Chem. Soc. 134(28), 11362-11365 (2012).
68. Bai C-G, Xu Y-T, Li N-N et al. Cysteine and its derivatives as New Delhi metallo-beta-lactamase-1 inhibitors. Curr. Enzyme Inhib. 11(1), 46-57 (2015).
69. Buynak JD, Chen H, Vogeti L et al. Penicillin-derived inhibitors that simultaneously target both metallo-and serine-lactamases. Bioorg. Med. Chem. Lett. 14(5), 1299-1304 (2004).
70. González MM, Kosmopoulou M, Mojica MF et al. Bisthiazolidines: a substrate-mimicking scaffold as an inhibitor of the NDM-1 carbapenemase. ACS Infect. Dis. 1(11), 544-554 (2015).
71. Brem J, Van Berkel SS, Aik W et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-lactamase inhibition. Nat. Chem. 6(12), 1084-1090 (2014).
72. Betts JW, Phee LM, Abdul Momin MHF et al. In vitro and in vivo activity of ML302F: a thioenolate inhibitor of VIM-subfamily metallo-lactamases. MedChemComm 7(1), 190-193 (2016).
73. Zhang Y-L, Yang K-W, Zhou Y-J, Lacuran AE, Oelschlaeger P, Crowder MW. Diaryl-substituted azolylthioacetamides: inhibitor discovery of New Delhi metallo-lactamase-1 (NDM-1). ChemMedChem 9(11), 2445-2448 (2014).
74. Yang S-K, Kang JS, Oelschlaeger P, Yang K-W. Azolylthioacetamide: a highly promising scaffold for the development of metallo-lactamase inhibitors. ACS Med. Chem. Lett. 6(4), 455-460 (2015).
75. Lassaux P, Hamel M, Gulea M et al. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-lactamases. J. Med. Chem. 53(13), 4862-4876 (2010).
76. Hussein WM, Fatahala SS, Mohamed ZM et al. Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Chem. Biol. Drug Des. 80(4), 500-515 (2012).
77. Mohamed MS, Hussein WM, Mcgeary RP, Vella P, Schenk G, Abd El-Hameed RH. Synthesis and kinetic testing of new inhibitors for a metallo-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Eur. J. Med. Chem. 46(12) 6075-6082 (2011).
78. Brem J, Cain R, Cahill S et al. Structural basis of metallo-lactamase, serine-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 7, 12406 (2016).
79. Hecker SJ, Reddy KR, Totrov M et al. Discovery of a cyclic boronic acid-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J. Med. Chem. 58(9), 3682-3692 (2015).
80. Johnson JW, Gretes M, Goodfellow VJ et al. Cyclobutanone analogues of-lactams revisited: insights into conformational requirements for inhibition of serine-and metallo-lactamases. J. Am. Chem. Soc. 132(8), 2558-2560 (2010).
81. Li G-B, Abboud MI, Brem J et al. NMR-filtered virtual screening leads to non-metal chelating metallo-lactamase inhibitors. Chem. Sci 8, 928-937 (2017).
82. Rydzik AM, Brem J, Van Berkel SS et al. Monitoring conformational changes in the NDM-1 metallo-lactamase by 19F NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 53(12), 3129-3133 (2014).
83. Ma J, Mcleod S, Maccormack K et al. Real-time monitoring of New Delhi metallo-lactamase activity in living bacterial cells by 1H NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 53(8), 2130-2133 (2014).